NCT03234491View on ClinicalTrials.gov

Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 22, 2017

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions
Post-Prandial HyperglycemiaPost-Prandial Hypoglycemia
Interventions
DEVICE

DiAS

Diabetes Assistant (DiAS) hybrid closed loop system.

DRUG

Afrezza low dose

Afrezza inhaled insulin low dose.

DRUG

Afrezza high dose

Afrezza inhaled insulin high dose.

Trial Locations (1)

06511

Yale Diabetes Research Clinic, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT03234491 - Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy | Biotech Hunter | Biotech Hunter